Core Viewpoint - The medical device sector is experiencing significant growth and investment opportunities, driven by recent regulatory approvals and technological advancements in brain-computer interface (BCI) technology [3][4][5]. Group 1: Market Performance - The medical device index ETF (159898) saw a 1.11% increase, with approximately 20 million yuan net inflow during trading [1]. - Key stocks in the medical device sector, such as Yirui Technology and Furu Medical, reported gains of 4.58% and 6.44% respectively, indicating strong market performance [1]. Group 2: Regulatory Developments - The National Medical Products Administration (NMPA) approved two high-value medical devices, enhancing clinical applications and technological development in the industry [3]. - Recent policies from major cities like Shanghai and Beijing aim to support the medical device industry, focusing on regulatory reforms and innovation [5]. Group 3: Technological Advancements - China has made significant progress in invasive brain-computer interface technology, becoming the second country after the U.S. to enter clinical trials [3]. - The global brain-computer interface market is projected to grow from approximately $2.62 billion in 2024 to $12.4 billion by 2034, with a compound annual growth rate of 17.35% [4]. Group 4: Investment Opportunities - Analysts suggest that the medical device sector may replicate the successful path of innovative pharmaceuticals, with a focus on innovation driving industry growth and global competitiveness [5]. - The medical device index ETF (159898) tracks a diverse range of leading companies in the sector, primarily focusing on A-share medical devices [7].

投资者是市场之本，上市公司是市场之基，二者共同构成资本市场高质量发展的源头活水。因此，监管 始终把固本强基摆在突出位置，以提升上市公司质量与增厚投资者回报为抓手，筑牢资本市场健康发展 根基。 立足这一核心目标，深圳证券交易所于2024年2月份正式启动"质量回报双提升"专项行动(以下简称"专 项行动")，旨在推动全体上市公司夯实发展质量、增强投资价值回报能力。如今，专项行动已落地近两 载，深市上市公司交出了一份怎样的提质增效答卷？ 数据显示，自专项行动启动以来，截至2025年11月底，已有471家公司披露"质量回报双提升"行动方 案，围绕增强主业意识、提高创新发展能力、提升投资者回报等方面提出一系列务实举措。从落地实效 看，相关公司经营业绩、研发创新与治理水平全面夯实，投资者回报力度持续加码，市场表现与估值水 平同步提升，构建起质量、回报与市场价值同向共振的良性循环格局。 三大路径提升公司质量 自专项行动启动以来，深市上市公司迅速响应、积极参与。以清晰目标锚定发展路径，以务实举措推进 落地见效，展现出"重质量、重回报"的鲜明特征。 从参与主体看，上述471家公司中，293家为深证成指成份股、88家入选沪深300 ...

格隆汇12月22日线上举办"科技赋能·资本破局"分享会。备受瞩目的卓越公司评选榜单隆重揭晓。其 中，格隆汇"金格奖"年度卓越公司评选中，迈瑞医疗(300760.SZ)荣获"年度创新力奖"奖项。 "年度创新力奖"旨在表彰资本市场最具有突破性、创新性的企业。创新是企业的核心竞争力，想要不 凡，就必须在技术研发、产品、商业模式等方面做出创新。本奖项从创新的广度、深度等多维度出发， 甄选出的企业都致力于探索前沿科技，开辟发展新路径，引领行业前行，推动社会进步。本次评选通过 定量数据分析和专家评审团等方式得出最终结果。 ...

Group 1 - The core focus of the event is the announcement of the "Annual Innovation Award" winners, recognizing companies with significant breakthroughs and innovations in the capital market [1] - The awarded companies include Guangfeng Technology, Corning Jereh Pharmaceutical-B, KEEP, Mindray Medical, Ruihe Zhizhi, AAC Technologies, 37 Interactive Entertainment, Tongwei Co., Xinghuan Technology-U, and Ginkgo Bioworks, with no specific ranking [1] - The "Annual Innovation Award" aims to highlight companies that excel in innovation across various dimensions, including technology research and development, products, and business models [1] Group 2 - The "Golden Award" evaluation is designed to create a reference list of the most valuable listed companies and unicorns in the investment community, covering all listed companies on major exchanges [2] - The evaluation includes companies listed on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, American Stock Exchange, and NASDAQ [2]

Group 1 - The consumer sector shows signs of stabilization and rebound, with the Wind Consumer Index rising by 1.33% last Friday and continuing to increase by 0.13% on Monday [1] - The retail and dairy sectors have seen significant increases, with the Wind Retail Index up 7.44% and the Wind Dairy Index up 5.35% since December [2] - Over 20 ETFs related to consumption themes have seen a net inflow of over 2.2 billion yuan since December, with the Fortune CSI Tourism Theme ETF receiving nearly 1.4 billion yuan [2] Group 2 - The long-term growth resilience of China's consumer market is evident, with retail sales expected to rise from 39.1 trillion yuan in 2020 to 48.3 trillion yuan in 2024, averaging a growth rate of 5.5% [3] - The Wind Consumer Index has underperformed this year, with a year-to-date increase of only 5.34%, significantly lower than other popular indices [3] - The average price-to-earnings ratio of the Wind Consumer Index is 23.31, well below the 10-year average of 28.56 [3] Group 3 - Institutions predict that the total net profit of the Wind Consumer Index constituents will reach nearly 460 billion yuan in 2025, an increase of 8.63% from the previous year, with growth rates expected to exceed 14% in 2026 and 2027 [4] - The Wind Consumer Index and the Wind Domestic Demand Upgrade Index consist of 87 stocks across 12 industries, including pharmaceuticals, automotive, electronics, and food and beverage [4] - The average year-to-date increase for the 87 constituent stocks is over 29%, driven primarily by high-performing electronics and pharmaceuticals stocks [4] Group 4 - As of December 19, the total financing balance for the 87 constituent stocks is close to 320 billion yuan, an increase of over 45% from the end of last year, with more than 70% of the stocks seeing increased financing [4] - Thirteen stocks with a financing balance increase of at least 20%, over 20 institutional surveys, and a year-to-date increase of less than 25% are primarily in the pharmaceuticals, food and beverage, and home appliance sectors [4] Group 5 - Huichuan Technology, Mindray Medical, and Hikvision have received the highest number of institutional surveys this year, with Huichuan Technology's stock price increasing nearly 25% [5] - Mindray Medical has been surveyed by nearly 1,000 institutions, while Hikvision has received over 500 surveys [5] - Dongpeng Beverage has been surveyed by nearly 270 institutions, with a stock price increase of around 12% [5]

Group 1 - The core viewpoint of the article highlights the significant increase in cash dividends among A-share listed companies, with total cash dividends reaching 2.61 trillion yuan this year, surpassing the total for 2024 and setting a historical record [2][3] - The improvement in the A-share dividend ecosystem is attributed to three main drivers: continuous enhancement of dividend guidelines by regulatory authorities, the implementation of the registration system that compels companies to improve governance quality, and a shift in investor structure towards a preference for stable returns [2][3] - A-share dividend amounts have shown a steady upward trend, with actual dividend amounts for 2022, 2023, and 2024 being 2.07 trillion yuan, 2.13 trillion yuan, and 2.4 trillion yuan respectively, reflecting a compound annual growth rate of 12%, significantly higher than the global average of 5% [2][3] Group 2 - Policy initiatives have been driving companies to enhance shareholder returns and encourage cash dividends, with the central economic work conference in late 2022 incorporating "dividends" into capital market reform directions, leading to a notable increase in the density and enforcement of dividend policies [3] - The improvement in corporate profitability is a crucial foundation for dividends, with A-share companies reporting a year-on-year revenue growth of 1.36% and net profit growth of 5.50% in the first three quarters of this year [3] - Leading companies in the A-share market, such as major state-owned banks and telecom operators, have emerged as key players in cash dividends, establishing themselves as benchmarks for stable returns [4] Group 3 - The distribution of dividends shows that sectors like banking, oil and gas, food and beverage, non-bank financials, telecommunications, and coal have all exceeded 100 billion yuan in dividend payouts, while new economy sectors like semiconductors and pharmaceuticals have also seen steady growth in dividends [5] - Companies like Mindray Medical and 37 Interactive Entertainment have demonstrated strong cash flow and commitment to shareholder returns, with Mindray having distributed dividends 13 times since its listing, totaling over 35.3 billion yuan [5] - Notable large dividend distributions have been observed, with Kweichow Moutai leading the market with a dividend of 2,395.70 yuan per hand, indicating a strong cash return for investors [5] Group 4 - The expected increase in dividend frequency and amounts by 2025 is driven by effective policy guidance and the establishment of a stable corporate foundation, pushing the A-share market towards a more mature focus on balancing investment and financing with shareholder returns [6] - The trend of cash dividends is anticipated to enhance the overall quality of the A-share market, with stable dividend expectations boosting investor confidence and aligning the A-share market more closely with mature markets, thereby attracting international capital [6]

证券研究报告 | 2025年12月22日 医药生物周报（25 年第 49 周） 优于大市 政策端支持服务消费力度提升，关注医疗服务相关机会 本周医药板块表现弱于整体市场，化学制药跌幅居前。本周全部 A 股下 跌 0.07%（总市值加权平均），沪深 300 下跌 0.28%，中小板指下跌 0.80%，创业板指下跌 2.26%，生物医药板块整体下跌 0.14%，生物医 药板块表现弱于整体市场。分子板块来看，化学制药下跌 1.74%，生物 制品下跌 0.67%，医疗服务上涨 0.55%，医疗器械上涨 1.16%，医药商 业上涨 4.94%，中药上涨 0.17%。医药生物市盈率（TTM）37.07x，处 于近 5 年历史估值的 79.04%分位数。 近两年我国密集出台支持服务消费的政策，围绕"稳增长、扩内需、提 质量"，持续释放服务消费潜力。政策一方面从供给侧入手，通过扩大 和优化服务供给、放宽准入、提升服务质量与效率，推动医疗、养老、 文旅等重点领域升级；另一方面通过财政、金融和价格等工具，加大对 居民消费和服务业主体的支持，降低成本、激发需求。在此背景下，"犒 赏经济"成为新亮点，居民在满足基本需求后，更愿为健康 ...

"年度创新力奖"旨在表彰资本市场最具有突破性、创新性的企业。创新是企业的核心竞争力，想要不 凡，就必须在技术研发、产品、商业模式等方面做出创新。本奖项从创新的广度、深度等多维度出发， 甄选出的企业都致力于探索前沿科技，开辟发展新路径，引领行业前行，推动社会进步。本次评选通过 定量数据分析和专家评审团等方式得出最终结果。 格隆汇以"全球视野，下注中国"为初衷，本次评选旨在打造出投资圈中最具参考价值的上市公司及独角 兽公司排行榜。此次"金格奖"上市公司评选覆盖港交所、上交所、深交所、纽交所、美国证券交易所、 纳斯达克证券交易所挂牌上市的全部上市公司及独角兽公司。 12月22日，格隆汇在线上举办"科技赋能·资本破局"分享会。本次分享会，备受瞩目的卓越公司评选榜 单将隆重揭晓，其中格隆汇"金格奖"年度卓越公司评选中，光峰科技(688007.SH)、康宁杰瑞制药- B(09966.HK)、KEEP(03650.HK)、迈瑞医疗(300760.SZ)、瑞和数智(03680.HK)、瑞声科技 (02018.HK)、三七互娱(002555.SZ)、通威股份(600438.SH)、星环科技-U(688031.SH)、云顶新耀 ...

中信建投证券研报指出，迈瑞医疗是国内医疗器械领域龙头公司，多个产品领域市占率国内领先。短期 来看，公司迎来长周期拐点，25Q3收入同比增速转正，25Q4增速有望进一步提升，2026年有望回归稳 健增长，在业绩修复、港股上市、战略转型背景下实现估值重塑。中长期来看，数智化、流水化、国际 化三大战略布局清晰，业务结构由设备销售为主向可持续、复购型收入模式升级，将打开更大的成长天 花板；公司研发创新、销售管理、国际化和并购能力已得到充分验证，全球市场份额将持续提升、加速 迈向全球医疗器械Top10，2026年港股上市将进一步提升全球影响力、优化股东结构。维持"买入"评 级。 ...

Core Viewpoint - The article highlights the recent measures taken by various regions to boost consumer spending ahead of the traditional consumption peak season, leading to a rebound in the large consumer sector in the capital market [1] Group 1: Market Performance - The large consumer index rose by 1.33% on December 19, significantly outperforming the Shanghai Composite Index [1] - Sub-sectors such as dairy, retail, and beverage manufacturing saw substantial increases, with Kweichow Moutai, a representative of large consumption, achieving a cumulative increase of 2.36% since December 10 [1] Group 2: Financing and Investment Trends - As of December 18, the total financing balance for the 87 constituent stocks of the large consumer index approached 320 billion yuan, representing an increase of over 45% compared to the end of last year, with over 70% of the financing targets seeing increased investment [1] - Notable stocks such as Rongchang Biologics, Sanhua Intelligent Control, and Sunshine Power experienced financing balance increases exceeding 100% [1] Group 3: Institutional Research and Stock Performance - There are 12 stocks with a financing balance increase of no less than 20%, having received research from 20 or more institutions this year, and with a year-to-date increase of less than 25% [1] - The leading companies in terms of institutional research are Huichuan Technology, Mindray Medical, and Hikvision, with the number of institutional research counts being 1654, 989, and 519 respectively [2]